FBXO9 and acute myeloid leukemia: Overall, we have identified Fbxo9 as a tumor suppressor of AML and shown that loss of its expression leads to increased proteasome activity and sensitivity to proteasome inhibition, thus implying that FBXO9 expression could be used as a biomarker to identify patients who would respond well to proteasome inhibition.